CD274 and non-small cell lung carcinoma: In NSCLC, retrospective analyses have shown TMB is independent of PD-L1 expression and seems to be potentially predictive of progression-free survival (PFS) benefit, but not of overall survival (OS), with checkpoint inhibitor monotherapy4,18–20.